Your browser doesn't support javascript.
loading
Interventions After First Post-Transplant Cutaneous Squamous Cell Carcinoma: A Proposed Decision Framework.
Bottomley, Matthew J; Massey, Paul R; Thuraisingham, Raj; Doyle, Alden; Rao, Swati; Bibee, Kristin P; Bouwes Bavinck, Jan Nico; Jambusaria-Pahlajani, Anokhi; Harwood, Catherine A.
Afiliação
  • Bottomley MJ; Chinese Academy of Medical Sciences Oxford Institute (CAMS-COI), Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Massey PR; Oxford Transplant Unit, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom.
  • Thuraisingham R; Cheyenne Skin Clinic, Cheyenne, WY, United States.
  • Doyle A; Department of Renal Medicine and Transplantation, Barts Health NHS Trust, London, United Kingdom.
  • Rao S; Department of Medicine, University of Virginia, Charlottesville, VA, United States.
  • Bibee KP; Department of Medicine, University of Virginia, Charlottesville, VA, United States.
  • Bouwes Bavinck JN; Department of Dermatology, School of Medicine, John Hopkins University, Baltimore, MD, United States.
  • Jambusaria-Pahlajani A; Department of Dermatology, Leiden University Medical Centre, Leiden, Netherlands.
  • Harwood CA; Division of Dermatology, Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
Transpl Int ; 35: 10880, 2022.
Article em En | MEDLINE | ID: mdl-36484063
ABSTRACT
Cutaneous squamous cell carcinoma (CSCC) is a major cause of morbidity and mortality after organ transplant. Many patients subsequently develop multiple CSCC following a first CSCC, and the risk of metastasis and death is significantly increased compared to the general population. Post-transplant CSCC represents a disease at the interface of dermatology and transplant medicine. Both systemic chemoprevention and modulation of immunosuppression are frequently employed in patients with multiple CSCC, yet there is little consensus on their use after first CSCC to reduce risk of subsequent tumors. While relatively few controlled trials have been undertaken, extrapolation of observational data suggests the most effective interventions may be at the time of first CSCC. We review the need for intervention after a first post-transplant CSCC and evidence for use of various approaches as secondary prevention, before discussing barriers preventing engagement with this approach and finally highlight areas for future research. Close collaboration between specialties to ensure prompt deployment of these interventions after a first CSCC may improve patient outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Células Escamosas Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Transpl Int Assunto da revista: TRANSPLANTE Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Células Escamosas Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Transpl Int Assunto da revista: TRANSPLANTE Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido